Skip to main content
SpringerLink
Log in

Do neuroleptic drugs still have a place in neurological therapy?

  • Editorial
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Altar CA, Boyar WC, Wasley A, Gerhardt SC, Liebman JM, Wood PL (1988) Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists. Naunyn-Schmiedeberg's Arch Pharmacol 338:162–168

    Google Scholar 

  2. Andén N-E (1972) Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anti-acetylcholine drugs. J Pharm Pharmacol 24:905–906

    Google Scholar 

  3. Andén N-E, Stock G (1973) Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25:346–348

    Google Scholar 

  4. Andén N-E, Corrodi H, Fuxe K, Ungerstedt U (1971) Importance of nervous impulse flow for the neuroleptic induced increase in amine turnover in central dopamine neurons. Eur J Pharmacol 15:193–199

    Google Scholar 

  5. Andersen PH, Nielsen EB, Gronvold FC, Braestrup C (1986) Some atypical neuroleptics inhibit [3H]SCH 23390 binding in vivo. Eur J Pharmacol 120:143–144

    Google Scholar 

  6. Asher SW, Aminoff MJ (1981) Tetrabenazine and movement disorders. Neurology 31:1051–1054

    Google Scholar 

  7. Asper H, Baggiolini HR, Burki HR, Lauener H, Ruch W, Stille G (1973) Tolerance phenomena with neuroleptics, catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol. Eur J Pharmacol 22:287–294

    Google Scholar 

  8. Atkinson JH (1989) Psychopharmacological agents in the treatment of pain syndromes. In Tollison CD (ed) Handbook of chronic pain management. Williams and Wilkins, Baltimore, pp 69–103

    Google Scholar 

  9. Baldessarini RJ (1985) Drugs and the treatment of psychiatric disorders. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics. McMillan, New York, pp 387–445

    Google Scholar 

  10. Barasi S, Duggal KN (1985) The effect of local and systemic application of dopaminergic agents on the tail flick latency in the rat. Eur J Pharmacol 117:287–294

    Google Scholar 

  11. Björklund A, Lindvall O (1984) Dopamine-containing systems in the CNS. In: Björklund A, Hökfelt T (eds) Handbook of chemical neuroanatomy, vol 2. Elsevier, Amsterdam, pp 55–122

    Google Scholar 

  12. Boyson SJ, McGonigle P, Luthin GR, Wolfe BB, Molinoff PB (1988) Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum. J Pharmacol Exp Ther 244:987–993

    Google Scholar 

  13. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol 20:140–144

    Google Scholar 

  14. Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607–1619

    Google Scholar 

  15. Chiodo LA, Bunney BS (1985) Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5:2539–2544

    Google Scholar 

  16. Chipkin RE, Latranyi MB (1987) Similarity of clozapine and SCH 23390 in reserpinized rats suggests a common mechanism of action. Eur J Pharmacol 136:371–375

    Google Scholar 

  17. Clow A, Jenner P, Theodorou A, Marsden CD (1979) Striatal dopamine receptors become supersensitive while rats are given trifluoperazine for six months. Nature 278:59–61

    Google Scholar 

  18. Dichgans J, Brinkmann A (1988) Dystonien and Athetosen. In: Brandt T, Dichgans J, Diener HC (eds) Therapie und Verlauf Neurologischer Erkrankungen. Kohlhammer, Stuttgart, pp 728–740

    Google Scholar 

  19. Fahn S (1973) Treatment of choreic symptoms with perphenazine. Adv Neurol 23:281–289

    Google Scholar 

  20. Fahn S, Marsden CD (1987) The treatment of dystonia. In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworths, London, pp 359–382

    Google Scholar 

  21. Fibiger HC, Lloyd KG (1984) Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci 7:462–464

    Google Scholar 

  22. Girotti F, Carella F, Scigliano G, Grassi MP, Soliveri P, Giovannini P, Parati E, Caraceni T (1984) Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. J Neurol Neurosurg Psychiatry 47:848–852

    Google Scholar 

  23. Goetz CG, Klawans HL (1982) Controversies in animal models of tardive dyskinesia. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworths, London, pp 263–276

    Google Scholar 

  24. Gomez-Perez FJ, Riell JA, Dies H, Rodriguez-Rivera JG, Gonzalez-Barranco J, Lozano-Castaneda O (1985) Nortryptiline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain 23:395–400

    Google Scholar 

  25. Groves PM, Wilson CJ, Young SJ, Rebec GV (1975) Self-inhibition by dopaminergic neurons. Science 190:522–529

    Google Scholar 

  26. Haase HJ (1961) Das therapeutische Achsensyndrom neuroleptischer Medikamente und seine Beziehungen zu extrapyramidaler Motorik. Fortschr Neurol Psychiatr 29:245–268

    Google Scholar 

  27. Heimer L (1983) The human brain and spinal cord. Springer, New York Berlin Heidelberg

    Google Scholar 

  28. Idänpään-Heikkila J, Alhava A, Olkinnora M, Palva IP (1977) Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11:193–198

    Google Scholar 

  29. Kebadian JW, Agui T, Oene JC van, Shigematsu K, Saavedra JM (1986) The D1 dopamine receptor: new perspectives. Trends Pharmacol Sci 7:96–99

    Google Scholar 

  30. Klockgether T, Schwarz M, Turski L, Ikonomidou-Turski C, Ossowska K, Heim C, Turski WA, Wüllner U, Sontag K-H (1987) Neurotransmitters in the basal ganglia: their role for the regulation of muscle tone. In: Carpenter MB, Jayaraman A (eds) The basal ganglia II. Plenum Press, New York, pp 185–202

    Google Scholar 

  31. Lane RF, Blaha CD (1988) Effects of chronic neuroleptic administration on nigrostriatal and mesocorticolimbic dopamine release: analysis using in vivo voltammetry. Ann NY Acad Sci 537:481–483

    Google Scholar 

  32. Langohr HD, Stöhr M, Petruch F (1982) An open and double-blind cross-over study on the efficacy of clomipramine (Anafranil) in patients with painful mono- and polyneuropathies. Eur Neurol 2:309–317

    Google Scholar 

  33. Marsden CD, Tarsy D, Baldessarini RJ (1975) Spontaneous and drug-induced movement disorders in psychotic patients. In: Benson DF, Blumer D (eds) Psychiatric aspects of neurological diseases. Grune and Stratton, New York, pp 219–265

    Google Scholar 

  34. Meltzer HY, Bastani B, Ramirez L, Matsubara S (1989) Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatr Neurol Sci 238:332–339

    Google Scholar 

  35. Monks R, Merskey H (1989) Psychotropic drugs. In: Wall PD, Melzack R (eds) Textbook of pain. Churchill Livingstone, Edinburgh, pp 702–721

    Google Scholar 

  36. Pakkenberg H, Fog R (1974) Spontaneous oral dykinesia. Arch Neurol 31:352–353

    Google Scholar 

  37. Penney JP, Young AB (1986) Striatal inhomogeneities and basal ganglia function. Mov Disord 1:3–15

    Google Scholar 

  38. Quinn N, Marsden CD (1984) A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 47:844–847

    Google Scholar 

  39. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JP, Young AB (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 85:5733–5737

    Google Scholar 

  40. Richelson E (1988) Neuroleptic binding to human brain receptors: relation to clinical effects. Ann NY Acad Sci 537:435–442

    Google Scholar 

  41. Rupniak NMJ, Jenner P, Marsden CD (1986) Acute dystonia induced by neuroleptic drugs. Psychopharmacology 88:403–419

    Google Scholar 

  42. Sayers AC, Bürki HR, Ruch W, Asper H (1976) Anticholinergic properties of antipsychotic drugs and their relation of extrapyramidal side effects. Psychopharmacology 51:15–22

    Google Scholar 

  43. Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci 235:60–64

    Google Scholar 

  44. Schott K, Ried S, Stevens I, Dichgans J (1989) Neuroleptically induced dystonia in Huntington's disease: a case report. Eur Neurol 29:39–40

    Google Scholar 

  45. Schumm F, Dichgans J, Zeller E (1981) Spontane orale Dyskinesien. Erfolgreiche Therapie mit Tetrabenazin (Nitoman). Arch Psychiatr Nervenkr 230:315–323

    Google Scholar 

  46. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug dosis and neuroleptic/dopamine receptors. Nature 261:717–719

    Google Scholar 

  47. Sigwald J, Bouttier D, Caille F (1959) Le traitement du zone et des algies zostériennes. Etude des résultats obtenus avec le lévomépromazine. Thérapie 14:818–824

    Google Scholar 

  48. Spokes EGS (1980) Neurochemical alterations in Huntington's disease. A study of post-mortem brain tissue. Brain 103:179–210

    Google Scholar 

  49. Taub A (1973) Relief of postherpetic neuralgia with psychotropic drugs. J Neurosurg 39:235–239

    Google Scholar 

  50. Weiner N (1985) Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics. McMillan, New York, pp 181–221

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologische Klinik, Universität Tübingen, Hoppe-Seyler-Strasse 3, D-7400, Tübingen, Germany

    T. Klockgether & J. Dichgans

Authors
  1. T. Klockgether
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Dichgans
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klockgether, T., Dichgans, J. Do neuroleptic drugs still have a place in neurological therapy?. J Neurol 237, 221–225 (1990). https://doi.org/10.1007/BF00314622

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00314622

Search

Navigation